Effectiveness of lamivudine and interferon-α combination therapy versus interferon-α monotherapy for the treatment of HBeAg-negative chronic hepatitis B patients: A randomized clinical trial

Journal of Microbiology, Immunology and Infection

Volumn 38, Issue 4, 2005, Pages 262-266

  Karabay, Oguz ^a   Tamer, Ali ^a   Tahtaci, Mustafa ^a   Vardi, Seref ^a   Celebi, Harika ^a  

^a ABANT IZZET BAYSAL UNIVERSITY   (Turkey)

Author keywords

Combination drug therapy; Hepatitis B; Hepatitis B antibodies; Interferon alpha; Lamivudine

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; ARTICLE; CHEMICAL ANALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; MONOTHERAPY; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; MALE; MIDDLE AGED;

EID: 24744432107     PISSN: 16841182     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Updated U.S. Public Health Service Guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep 2001;50(RR-11):1-42.
2. Lok AS, McMahon BJ, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Chronic hepatitis B. Hepatology 2001;34:1225-41.
3. McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 2001;135:759-68.
4. Saruc M, Ozden N, Yuceyar H. Thymosin in the treatment of HBeAg-negative chronic hepatitis B. Med Sci Monit 2003;9:198-202.
5. Yuen MF, Lai CL. Current and future antiviral agents for chronic hepatitis B. J Antimicrob Chemother 2003;51:481-5.
6. Malik AH, Lee WM. Chronic hepatitis B virus infection: treatment strategies for the next millennium. Ann Intern Med 2000;132:723-31.
7. Hadziyannis SJ, Papatheodoridis GV, Vassilopoulos D. Treatment of HBeAg-negative chronic hepatitis B. Semin Liver Dis 2003;23:81-8.
8. Farrell G. Hepatitis B e antigen seroconversion: effects of lamivudine alone or in combination with interferon alpha. J Med Virol 2000;61:374-9.
9. Serfaty L, Thabut D, Zoulim F, Andreani T, Chazouilleres O, Carbonell N, et al. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study. Hepatology 2001;34:573-7.
10. van Nunen AB, Janssen HL, Wolters LM, Niesters HG, de Man RA, Schalm SW. Is combination therapy with lamivudine and interferon-alpha superior to monotherapy with either drug? Antiviral Res 2001;52:139-46.
11. Fact sheets: Hepatitis B. Geneva: World Health Organization, October 2000.
12. Jaboli MF, Fabbri C, Liva S, Azzaroli F, Nigro G, Giovanelli S, et al. Long-term alpha interferon and lamivudine combination therapy in non-responder patients with anti-HBe-positive chronic hepatitis B: results of an open, controlled trial. World J Gastroenterol 2003;9:1491-5.
13. Mutimer D, Dowling D, Cane P, Ratcliffe D, Tang H, O'Donnell K, et al. Additive antiviral effects of lamivudine and alpha-interferon in chronic hepatitis B infection. Antivir Ther 2000;5:273-7.
14. Petry W, Erhardt A, Heintges T, Haussinger D. New developments in therapy of chronic hepatitis B. When are nucleoside analogs indicated? Z Gastroenterol 2000;38:77-87. [in German]
15. Dikici B, Bosnak M, Bosnak V, Dagli A, Davutoglu M, Yagci RV, et al. Comparison of treatments of chronic hepatitis B in children with lamivudine and α-interferon combination and á-interferon alone. Pediatr Int 2002;44:517-21.
16. Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000;46:562-8.
17. Tatulli I, Francavilla R, Rizzo GL, Vinciguerra V, Ierardi E, Amoruso A, et al. Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B. J Hepatol 2001;35:805-10.
18. Santantonio T, Niro GA, Sinisi E, Leandro G, Insalata M, Guastadisegni A, et al. Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. J Hepatol 2002;36:799-804.
19. Schiff ER, Dienstag JL, Karayalcin S, Grimm IS, Perrillo RP, Husa P, et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol 2003;38:818-26.
20. Schenker BM, Zamora S, Benkebil F. Treatment of chronic hepatitis B in children with a combination of lamivudine and alpha interferon is not better than with alpha interferon alone. 34th Annual Meeting of ESPGHAN, May 9-12, 2001, Geneva, Switzerland.
21. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63.
22. Lim SG, Wai CT, Rajnakova A, Kajiji T, Guan R. Fatal hepatitis reactivation following discontinuation of nucleoside anologues for chronic hepatitis B. Gut 2002;51:597-9.
23. Ayres A, Bartholomeusz A, Lau G, Lam KC, Lee JY, Locarnini S. Lamivudine and famciclovir resistant hepatitis B virus associated with fatal hepatic failure. J Clin Virol 2003;27:111-6.